Scarica l'app Stockscreener
0.8436
8.88%
0.0688
Pre-mercato:
.92
0.0764
+9.06%
Precedente Chiudi:
$0.7748
Aprire:
$0.79
Volume 24 ore:
567.99K
Relative Volume:
1.09
Capitalizzazione di mercato:
$72.77M
Reddito:
-
Utile/perdita netta:
$-50.21M
Rapporto P/E:
-0.4428
EPS:
-1.9053
Flusso di cassa netto:
$-16.61M
1 W Prestazione:
+7.77%
1M Prestazione:
+13.16%
6M Prestazione:
-26.64%
1 anno Prestazione:
-33.05%
Intervallo 1D:
$0.79
$0.87
Intervallo di 1 settimana:
$0.7293
$0.87
Portata 52W:
$0.694
$2.18
Rein Therapeutics Inc Stock (RNTX) Company Profile
Nome
Rein Therapeutics Inc
Settore
Industria
Telefono
(737) 802-1989
Indirizzo
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
0.8436 | 68.46M | 0 | -50.21M | -16.61M | -1.9053 |
VRTX
Vertex Pharmaceuticals Inc
|
557.96 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
843.47 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,053.46 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
148.87 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.87 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2017-07-24 | Iniziato | BofA/Merrill | Buy |
| 2017-07-24 | Iniziato | Jefferies | Buy |
| 2017-07-24 | Iniziato | William Blair | Outperform |
Rein Therapeutics Inc Borsa (RNTX) Ultime notizie
Rein Therapeutics Inc (NASDAQ: RNTX) Stock Price, News & Analysis - kalkine.ca
Rein (RNTX) Quarter in Focus: The Available Earnings Metric Delivers a Beat on the Day; Post-Report: Shares Move 0.88% Higher in the Current UpdateGuidance Accuracy Score - vinanet.vn
Rein Therapeutics receives FDA fast track for IPF drug LTI-03 - Investing.com Australia
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - The Manila Times
Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival - Stock Titan
Equities Analysts Set Expectations for RNTX FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for RNTX FY2030 Earnings? - MarketBeat
RNTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Rein Therapeutics (NASDAQ:RNTX) Given "Buy" Rating at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy on Rein Therapeutics stock By Investing.com - Investing.com Canada
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates as Stock Climbs 2.35%Tech Earnings Analysis - Vinanet
Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat
Rein Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Rein Therapeutics (RNTX) Holds at $0.79 as Range-Bound Trading PersistsVWAP Bounce - Vinanet
Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - Quiver Quantitative
Press Release: Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView
RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
RNTX Q1 2026 Earnings: Narrowed Per-Share Loss Beats Consensus by Nearly 62%Financial Health Score - vinanet.vn
RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Improved Capital DisciplineOne-Time Loss Impact - vinanet.vn
Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9%Here's Why - MarketBeat
Rein Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Certain Stock Options of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Certain Warrants of Rein Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026. - marketscreener.com
Rein Therapeutics Inc (RNTX) Stock News Today - TradingKey
RNTX PE Ratio & Valuation, Is RNTX Overvalued - Intellectia AI
Rein Therapeutics’ LTI-03 study published in Nature Communications - Investing.com
Rein Therapeutics’ LTI-03 study published in Nature Communications By Investing.com - Investing.com Canada
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications - Yahoo Finance
Rein's Inhaled LTI-03 Reduced Lung-Scarring Markers After 14 Days - Stock Titan
Rein Therapeutics (RNTX) Dips 2.76% to $0.74, Pressing Against Key SupportSuperTrend - dars.gov.et
Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rein Therapeutics Inc (RNTX) Cash Flow - TradingKey
Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rein Therapeutics Inc (RNTX) Income Statement - TradingKey
Rein Therapeutics Inc (RNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNTX|Rein Therapeutics Inc|Price:0.791|Chg%:-0.009 - TradingKey
Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rein Therapeutics (RNTX) Proxy filing Summary - Quartr
Rein Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNTX - TradingView
RNTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseFree Cash Flow Trends - vinanet.vn
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rein Therapeutics (RNTX) Q4 2025 earnings summary - Quartr
Rein Therapeutics Inc Azioni (RNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rein Therapeutics Inc Azioni (RNTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| VON RICKENBACH JOSEF H | Director |
May 22 '26 |
Buy |
1.05 |
15,950 |
16,708 |
34,824 |
| VON RICKENBACH JOSEF H | Director |
May 27 '26 |
Buy |
1.07 |
4,500 |
4,819 |
62,514 |
| VON RICKENBACH JOSEF H | Director |
May 21 '26 |
Buy |
1.04 |
3,420 |
3,564 |
18,874 |
| WINDSOR JAMES BRIAN | See Remarks |
Apr 30 '26 |
Buy |
1.00 |
25,000 |
25,000 |
27,046 |
| Voss Capital, LP | 10% Owner |
Nov 14 '25 |
Buy |
1.22 |
104,183 |
127,593 |
926,441 |
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
0.64%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):